DE69433007D1 - Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus - Google Patents

Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus

Info

Publication number
DE69433007D1
DE69433007D1 DE69433007T DE69433007T DE69433007D1 DE 69433007 D1 DE69433007 D1 DE 69433007D1 DE 69433007 T DE69433007 T DE 69433007T DE 69433007 T DE69433007 T DE 69433007T DE 69433007 D1 DE69433007 D1 DE 69433007D1
Authority
DE
Germany
Prior art keywords
peptides
virus
cytotoxic
hepatitis
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433007T
Other languages
English (en)
Other versions
DE69433007T2 (de
Inventor
Francis V Chisari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of DE69433007D1 publication Critical patent/DE69433007D1/de
Application granted granted Critical
Publication of DE69433007T2 publication Critical patent/DE69433007T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/223—Hepatitis related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE1994633007 1993-02-26 1994-02-25 Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus Expired - Lifetime DE69433007T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2412093A 1993-02-26 1993-02-26
US24120 1993-02-26
PCT/US1994/002195 WO1994019011A1 (en) 1993-02-26 1994-02-25 Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus

Publications (2)

Publication Number Publication Date
DE69433007D1 true DE69433007D1 (de) 2003-09-11
DE69433007T2 DE69433007T2 (de) 2004-06-09

Family

ID=21818965

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1994634954 Expired - Lifetime DE69434954T2 (de) 1993-02-26 1994-02-25 Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus
DE1994633007 Expired - Lifetime DE69433007T2 (de) 1993-02-26 1994-02-25 Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1994634954 Expired - Lifetime DE69434954T2 (de) 1993-02-26 1994-02-25 Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus

Country Status (11)

Country Link
US (1) US5788969A (de)
EP (2) EP0687182B1 (de)
JP (2) JP3657603B2 (de)
KR (1) KR960700745A (de)
CN (1) CN1118573A (de)
AT (1) ATE359089T1 (de)
AU (1) AU695261B2 (de)
DE (2) DE69434954T2 (de)
ES (1) ES2204912T3 (de)
NZ (1) NZ263030A (de)
WO (1) WO1994019011A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US6235288B1 (en) * 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
JP2002509157A (ja) * 1998-01-19 2002-03-26 モガン バイオテクノロジー リサーチ インスティチュート Ｂ型肝炎ウイルスのｘプロテインに由来するペプチド抗原を含むリポソーム
WO1999058658A2 (en) * 1998-05-13 1999-11-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
EP1244465A4 (de) * 1999-12-21 2005-01-12 Epimmune Inc Induzierung von zellulärer immunantwort gegen prostatakrebsantigenen mittels peptid- und nukleinsäureverbindungen
KR100455902B1 (ko) * 2001-07-18 2004-11-12 주식회사 펩트론 Ｂ형 간염 바이러스 표면단백질 프리에스-1 유래의 펩타이드
CN1305527C (zh) * 2003-11-21 2007-03-21 薛平 乙型肝炎治疗疫苗及其制备方法
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
US20090023895A1 (en) * 2006-02-07 2009-01-22 Nec Corporation Hla-binding peptide, precursor thereof, and dna fragment and recombinant vector coding for said hla-binding peptide
US8324345B2 (en) 2006-10-12 2012-12-04 Nec Corporation HLA-binding peptide, precursor thereof, DNA fragment and recombinant vector encoding the same
US20110110974A1 (en) * 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
EP2461826A2 (de) 2009-08-07 2012-06-13 Transgene SA Zusammensetzung zur behandlung von hbv-infektionen
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
EP0293201A3 (de) * 1987-05-26 1990-02-28 The Wistar Institute Methode zur Impfung gegen Hepatitis-B-Virus
EP0326111A3 (de) * 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptid-Derivate, immunogenisch gemacht bei Verabreichung zusammen mit Alaun als Zusatzmittel
CA2157510A1 (en) * 1993-03-05 1994-09-15 Howard M. Grey Hla-a2.1 binding peptides and their uses
ES2180576T3 (es) * 1993-04-27 2003-02-16 United Biomedical Inc Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
DE69430315T2 (de) * 1993-08-06 2002-11-21 Epimmune, Inc. Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl

Also Published As

Publication number Publication date
JP3616390B2 (ja) 2005-02-02
EP0687182A1 (de) 1995-12-20
EP1375511B1 (de) 2007-04-11
DE69434954D1 (de) 2007-05-24
EP1375511A2 (de) 2004-01-02
EP0687182A4 (de) 1997-03-12
US5788969A (en) 1998-08-04
EP1375511A3 (de) 2005-03-02
DE69433007T2 (de) 2004-06-09
DE69434954T2 (de) 2007-12-20
JP2004161778A (ja) 2004-06-10
JPH08507080A (ja) 1996-07-30
AU6355994A (en) 1994-09-14
CN1118573A (zh) 1996-03-13
WO1994019011A1 (en) 1994-09-01
NZ263030A (en) 1997-10-24
EP0687182B1 (de) 2003-08-06
ES2204912T3 (es) 2004-05-01
JP3657603B2 (ja) 2005-06-08
AU695261B2 (en) 1998-08-13
KR960700745A (ko) 1996-02-24
ATE359089T1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
DE69431665D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
PT725824E (pt) Epitopos de celulas t humanas imunodominantes do virus da hepatite c
ATE320444T1 (de) Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
FR2632863B2 (fr) Virus du fowlpox recombinant et vaccins derives de ces virus
ATE177755T1 (de) Hybrides protein zwischen cs aus plasmodium und hbsag
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
FR2620459B1 (fr) Virus recombinant de la vaccine
MX9101810A (es) Vacuna contra virus de anemia de polio y diagnostico
ITMI913092A1 (it) Vaccino di poxvirus ricombinante del virus del morbillo
ATE220332T1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
ITRM910546A0 (it) Epitopi della proteina env del virus dell'epatite c
ATE136933T1 (de) Rekombinante hbsag hybridpartikel, die morphologische eigenschaften von hbsag-antigen haben und eine immunogene sequenz enthalten, die neutralisierende antikörper gegen hiv induziert oder die von diesen antikörpern erkannt ist, nukleotide sequenzen, die diese partikel codieren und sie enthaltende impfstoffe
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
DK0498905T3 (da) Tilpassede epitoper af human immundeficiensvirus kappeglycoprotein gp120
KR900016262A (ko) 포유류 중의 HIV-억제 항체 유도성 사람 면역 결핍 바이러스(HIV) env-암호화된 펩타이드
MC2306A1 (fr) Peptides bloquant les infections par le virus de l'immunodeficience humaine et methode de leur utilisation
RU94032103A (ru) Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации

Legal Events

Date Code Title Description
8364 No opposition during term of opposition